PGNX
Interesante. Si me creo lo que cuenta el artículo, parece una buena opción de compra para estar comprado a medio plazo, pero no tengo conocimiento para evaluarlo... ¿opinión de alguno de los expertos médicos del foro?
Por cierto, ahora mismo no sube más que un 2%.
CYTX sobre estas no tienes nada nuevo,no Ana?
PGNX
Llevan subiendo desde apertura sin corregir una miaja.
Dentro a 4,65 y a esperar acontecimientos.
PGNX
CYTX
La verdad es que hace tiempo que no me la miro. Habrá que echarle un vistado a los resultados del ATHENA y ver si el suelo en que parece que está es sólido, aunque después de un R/S... Miraré los foros.
-Hizo colocación hace nada a 2,55, que ya está cerrada.
-Estudio preclínico de mejora del tejido y la función urinaria
http://finance.yahoo.com/news/cytori-cell-therapy-leads-improved-110000532.html
-Presentation of Twelve Month Pilot Trial Data of Cytori® Cell Therapy™ for ACL Reconstruction
http://finance.yahoo.com/news/presentation-twelve-month-pilot-trial-110000429.html
-Limited Approval for Osteoarthritis in Japan
http://finance.yahoo.com/news/cytori-cell-therapy-receives-limited-090000934.html
Lo más importante: results from the ATHENA Trials
http://finance.yahoo.com/news/cytori-athena-trial-chronic-ischemic-110000791.html
CANF
Can-Fite BioPharma announces its Phase II clinical trial of CF101 failed to meet its primary endpoint (CANF) :
CF101 is currently under development for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis and psoriasis.
In this trial, no statistically significant differences were found between the CF101 treated group and the placebo group in the primary endpoint of lowering intra ocular pressure.
CF101 was found to have a favorable safety profile and was well tolerated.
"We are disappointed that CF101 failed to meet its primary endpoint, and based on these overall results we see no immediate path forward in glaucoma," said Pnina Fishman, PhD, CEO of Can Fite BioPharma.
CYTX
El ATHENA pinta fatal.
Improvements in the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
3 months = -4.7 (-20.3, 10.9) (p=0.54)
6 months = -9.4 (-22.5, 3.8) (p=0.154)
12 months = -16.3 (-31.7, -1.0) (p=0.038)
Regarding safety, 18 of 31 patients (58.1%) were reported to have at least one serious adverse event during the trial (Cytori Cell Therapy 9/17 (52.9%), placebo 9/14 (64.3%)). Major Adverse Cardiovascular Events (MACE) occurred in 6/17 (35.3%) of ADRC patients and 3/14 (21.4%) of placebo patients. Two fatal events were reported during the trial with both occurring in the Cytori Cell Therapy group (myocardial ischemia – day 2 post-procedure, decompensation of heart failure – day 291 post-procedure).
RVNC
Dentro unas poquitas con las que salvé de ESPR, [email protected].
Próximas entradas seguramente en DVAX y FGEN si corrigen algo más.
A investigar para futuro PRTO y nanos OCRX y BSTG.
